MPP hydrochloride|西域试剂

MPP hydrochloride,99.58%

产品编号：Bellancom-103454B| 分子式：C₂₉H₃₂ClN₃O₃| 分子量：506.04

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-103454B	￥3500.00	杭州北京（现货）
Bellancom-103454B	￥5550.00	杭州北京（现货）
Bellancom-103454B	￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MPP hydrochloride

产品介绍

MPP hydrochloride 是一种强效的选择性 ER (雌激素受体)调节剂。MPP hydrochloride 可诱导子宫内膜癌和 oLE 细胞凋亡。MPP hydrochloride 可逆转 β - 雌激素的积极作用。在体内，MPP hydrochloride 对小鼠子宫 ERalpha 具有激动剂和拮抗剂的混合作用。

生物活性

MPP hydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP hydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP hydrochloride reverses the the positive effects of beta-estradiol. MPP hydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo.

体外研究

MPP (1, 5, 10, 25, 50 and 100 µM; 24 h) decreases cell viability with an IC₅₀ value of 20.01 µM in RL95-2 cells.
MPP dihydrochloride shows antiproliferative activity at a concentration of 10 μM in RL95-2 cells.
MPP dihydrochloride (20 µM; 24 h) reduces the phosphorylation of ERα, while it does not alter the phosphorylation of Akt. MPP dihydrochloride reduces the ratio of p-ERα/ERα.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	RL95-2 endometrium cancer cells
Concentration:	1, 5, 10, 25, 50 and 100 µM
Incubation Time:	24 hours
Result:	The treatment with 25 µM, 50 µM and 100 µM for 24 h decreased cell viability significantly. However, cell viability was not significantly changed by MPP dihydrochloride at concentration below 25 µM.

Cell Proliferation Assay

Cell Line:	RL95-2 endometrium cancer cells
Concentration:	10, 15, 20 and 25 µM
Incubation Time:	72 hours
Result:	Showed antiproliferative activity at a concentration of 10 μM.

Western Blot Analysis

Cell Line:	RL95-2 endometrium cancer cells
Concentration:	20 µM
Incubation Time:	24 hours
Result:	Reduced the phosphorylation of ERα, while it did not alter the phosphorylation of Akt. Reduced the ratio of p-ERα/ERα compared to the control group.

体内研究
(In Vivo)

MPP (Low dose 20 μg/kg body weight or high dose 200 μg/kg body weight) leads to a dose-dependent attenuation of percent prepulse inhibition (PPI).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6N mice at the age of 9-10 weeks
Dosage:	Low dose (20 μg/kg body weight) or high dose (200 μg/kg body weight)
Administration:	Administered subcutaneously (s.c.) injected; injection volume of 5 mL/kg; 60 min before PPI testing
Result:	Led to a dose-dependent attenuation of percent PPI. Pretreatment with 200 μg/kg reduced the mean percent PPI scores by ~30%.

体内研究

MPP (Low dose 20 μg/kg body weight or high dose 200 μg/kg body weight) leads to a dose-dependent attenuation of percent prepulse inhibition (PPI).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6N mice at the age of 9-10 weeks
Dosage:	Low dose (20 μg/kg body weight) or high dose (200 μg/kg body weight)
Administration:	Administered subcutaneously (s.c.) injected; injection volume of 5 mL/kg; 60 min before PPI testing
Result:	Led to a dose-dependent attenuation of percent PPI. Pretreatment with 200 μg/kg reduced the mean percent PPI scores by ~30%.

体内研究

MPP (Low dose 20 μg/kg body weight or high dose 200 μg/kg body weight) leads to a dose-dependent attenuation of percent prepulse inhibition (PPI).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6N mice at the age of 9-10 weeks
Dosage:	Low dose (20 μg/kg body weight) or high dose (200 μg/kg body weight)
Administration:	Administered subcutaneously (s.c.) injected; injection volume of 5 mL/kg; 60 min before PPI testing
Result:	Led to a dose-dependent attenuation of percent PPI. Pretreatment with 200 μg/kg reduced the mean percent PPI scores by ~30%.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (494.03 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9761 mL	9.8806 mL	19.7613 mL
5 mM	0.3952 mL	1.9761 mL	3.9523 mL
10 mM	0.1976 mL	0.9881 mL	1.9761 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.11 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.11 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.11 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.11 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。